Literature DB >> 31155642

Counterpoint: Keeping the Demons at Bay When Handling Time-Varying Exposures-Beyond Avoiding Immortal Person-Time.

Jessie K Edwards1, Phyo T Htoo1, Til Stürmer1.   

Abstract

The potential for immortal time bias is pervasive in epidemiologic studies with left truncation or time-varying exposures. Unlike other biases in epidemiologic research (e.g., measurement bias, confounding due to unmeasured factors, and selection based on unmeasured predictors of the outcome), immortal time bias can and should be avoided by the correct assignment of person-time during follow up. However, even when handing person-time correctly, allowing late entry into a study or into an exposure group can open the door to more insidious sources of bias, some of which we explore here. Clear articulation of the study question, including the treatment plans of interest, can provide navigation around these sources of bias and elucidate the assumptions needed for inference given the available data. Here, we use simulated data to illustrate the assumptions required under various approaches to estimate the effect of a time-varying treatment and describe how these assumptions relate to the assumptions necessary to estimate single sample rates and risks in settings with censoring and truncation.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  causality; epidemiologic methods; risk; survival analysis

Mesh:

Year:  2019        PMID: 31155642      PMCID: PMC7415259          DOI: 10.1093/aje/kwz066

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   5.363


  18 in total

1.  Counterpoint: the treatment decision design.

Authors:  M Alan Brookhart
Journal:  Am J Epidemiol       Date:  2015-10-26       Impact factor: 4.897

2.  Left-truncated data with age as time scale: an alternative for survival analysis in the elderly population.

Authors:  R Lamarca; J Alonso; G Gómez; A Muñoz
Journal:  J Gerontol A Biol Sci Med Sci       Date:  1998-09       Impact factor: 6.053

3.  Selection Bias Due to Loss to Follow Up in Cohort Studies.

Authors:  Chanelle J Howe; Stephen R Cole; Bryan Lau; Sonia Napravnik; Joseph J Eron
Journal:  Epidemiology       Date:  2016-01       Impact factor: 4.822

4.  Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available.

Authors:  Miguel A Hernán; James M Robins
Journal:  Am J Epidemiol       Date:  2016-03-18       Impact factor: 4.897

5.  Per-Protocol Analyses of Pragmatic Trials.

Authors:  Miguel A Hernán; James M Robins
Journal:  N Engl J Med       Date:  2017-10-05       Impact factor: 91.245

Review 6.  Observational Studies of Inhaled Corticosteroid Effectiveness in COPD: Lessons Learned.

Authors:  Samy Suissa; Pierre Ernst
Journal:  Chest       Date:  2018-04-19       Impact factor: 9.410

Review 7.  Nonexperimental comparative effectiveness research using linked healthcare databases.

Authors:  Til Stürmer; Michele Jonsson Funk; Charles Poole; M Alan Brookhart
Journal:  Epidemiology       Date:  2011-05       Impact factor: 4.822

8.  Paradoxical relations of drug treatment with mortality in older persons.

Authors:  R J Glynn; E L Knight; R Levin; J Avorn
Journal:  Epidemiology       Date:  2001-11       Impact factor: 4.822

9.  The hazards of hazard ratios.

Authors:  Miguel A Hernán
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

10.  Association of Cataract Surgery With Mortality in Older Women: Findings from the Women's Health Initiative.

Authors:  Victoria L Tseng; Rowan T Chlebowski; Fei Yu; Jane A Cauley; Wenjun Li; Fridtjof Thomas; Beth A Virnig; Anne L Coleman
Journal:  JAMA Ophthalmol       Date:  2018-01-01       Impact factor: 7.389

View more
  1 in total

1.  Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.

Authors:  Phyo T Htoo; John Buse; Matthew Cavender; Tiansheng Wang; Virginia Pate; Jess Edwards; Til Stürmer
Journal:  J Am Heart Assoc       Date:  2022-02-08       Impact factor: 6.106

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.